Impact on abiraterone pharmacokinetics (PK) and safety: Open-label drug-drug interaction (DDI) studies with ketoconazole and rifampicin

被引：0
|
作者：
Chien, C. [1 ]
Bernard, A. [2 ]
Vaccaro, N. [3 ]
Acharya, M. [2 ]
Jiao, J. [4 ]
Monbaliu, J. [5 ]
De Vries, R. [6 ]
Stieltjes, H. [6 ]
Yu, M. K. [7 ]
Tran, N. P. [7 ]
机构：
[1] Janssen Res & Dev, Clin Pharmacol, Titusville, NJ USA
[2] Janssen Res & Dev, Clin Pharmacol, Raritan, NJ USA
[3] Janssen Res & Dev, Clin Pharmacol, San Diego, CA USA
[4] Janssen Res & Dev, Biometr & Reporting, Raritan, NJ USA
[5] Janssen Res & Dev, Preclin Project Dev, Beerse, Belgium
[6] Janssen Res & Dev, Bioanal, Beerse, Belgium
[7] Janssen Res & Dev, WC Clin Oncol, Los Angeles, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2917
引用
收藏
页码：S702 / S703
页数：2
相关论文
共 50 条
  • [41] A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors
    Liao, Mingxiang
    Jeziorski, Krzysztof G.
    Tomaszewska-Kiecana, Monika
    Lang, Istvan
    Jasiowka, Marek
    Skarbova, Viera
    Centkowski, Piotr
    Ramlau, Rodryg
    Gornas, Maria
    Lee, John
    Edwards, Sarah
    Habeck, Jenn
    Nash, Eileen
    Grechko, Nikolay
    Xiao, Jim J.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (05) : 887 - 897
  • [42] AN OPEN-LABEL DRUG-DRUG INTERACTION STUDY BETWEEN INCB057643, A BRD INHIBITOR, AND WARFARIN IN HEALTHY SUBJECTS.
    Epstein, N.
    Ji, T.
    Chen, X.
    Punwani, N.
    Yeleswaram, S.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S56 - S56
  • [43] Phase I/IIa, randomized, open-label, drug-drug interaction study of trabectedin and rifampin in patients with advanced cancer.
    Staddon, Arthur P.
    Parekh, Trilok V.
    Knoblauch, Roland Elmar
    Keung, Chi
    Bernard, Apexa
    Aymes, Ana L.
    Phelps, Charles
    Sharma, Sunil
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study
    Moreno, Irene
    Hernandez, Tatiana
    Calvo, Emiliano
    Fudio, Salvador
    Kahatt, Carmen
    Martinez, Sara
    Iglesias, Jorge Luis
    Calafati, Roman Octavio
    Perez-Ramos, Laura
    Montilla, Lola
    Zeaiter, Ali
    Lubomirov, Rubin
    [J]. MARINE DRUGS, 2024, 22 (04)
  • [45] Impact of Obesity on the Drug-Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers
    Berton, Mattia
    Bettonte, Sara
    Stader, Felix
    Battegay, Manuel
    Marzolini, Catia
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (07):
  • [46] Drug-drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open-label, randomized, 6-sequence, 3-period crossover studies
    Kamimura, Tomohiro
    Hounslow, Neil
    Suganami, Hideki
    Tanigawa, Ryohei
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (08):
  • [47] Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies
    Munoz, Flor M.
    Anderson, Evan J.
    Deville, Jaime G.
    Clinch, Barry
    Kamal, Mohamed A.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (07) : 531 - 540
  • [48] Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction
    Al-Enezi, Bashayer F.
    Al-Hasawi, Nada
    Matar, Kamal M.
    [J]. PLOS ONE, 2023, 18 (01):
  • [49] In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity
    Monbaliu, Johan
    Gonzalez, Martha
    Bernard, Apexa
    Jiao, James
    Sensenhauser, Carlo
    Snoeys, Jan
    Stieltjes, Hans
    Wynant, Inneke
    Smit, Johan W.
    Chien, Caly
    [J]. DRUG METABOLISM AND DISPOSITION, 2016, 44 (10) : 1682 - 1691
  • [50] COADMINISTRATION OF CIMETIDINE WITH MIROGABALIN IN HEALTHY SUBJECTS: RESULTS FROM A PHASE I, RANDOMIZED, OPEN-LABEL, DRUG-DRUG INTERACTION STUDY.
    Tachibana, M.
    Yamamura, N.
    Hsu, C.
    Warren, V.
    Dishy, V.
    Zahir, H.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S49 - S49
12345